Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting

Therapeutic Drug Monitoring

Volumn 24, Issue 4, 2002, Pages 545-553

  Reis, Margareta ^a   Lundmark, Jöns ^a   Björk, Henrik ^a   Bengtsson, Finn ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Clinical setting; Drug interactions; Naturalistic variance; Serum concentration; Therapeutic drug monitoring; Venlafaxine

Indexed keywords

ALIMEMAZINE; ALPRAZOLAM; BUSPIRONE; CENTRAL STIMULANT AGENT; CYTOCHROME P450 2D6; DESVENLAFAXINE; DIAZEPAM; DRUG METABOLITE; FLUNITRAZEPAM; FLUPENTIXOL; HYDROXYZINE; LEVOMEPROMAZINE; LITHIUM; N,O DINORVENLAFAXINE; NITRAZEPAM; NORVENLAFAXINE; OMEPRAZOLE; OXAZEPAM; PROPIOMAZINE; UNCLASSIFIED DRUG; VENLAFAXINE; ZOLPIDEM; ZOPICLONE;

ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISPOSITION; FEMALE; GENDER; HUMAN; MALE; PRIORITY JOURNAL; SMOKING; STEADY STATE; SWEDEN;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; SEX FACTORS; SMOKING; STEREOISOMERISM;

EID: 0036337642     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200208000-00014     Document Type: Article

References (31)

1. Venlafaxine. A review of its pharmacology and therapeutic potential in depression
2. Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression
3. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative
4. Biochemical, neurophysiological, and behavioral effects of Wy-45.233 and other identified metabolites of the antidepressant venlafaxine
5. Venlafaxine oxidation in vitro is catalysed by CYP2D6
6. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: Effect of metabolic inhibitors and SSRI antidepressants
7. Venlafaxine serum levels and CYP2D6 genotype
8. A therapeutic drug monitoring routine clearly improves dosing, postmarketing surveillance and drug safety for SSRIs
9. A racemic HPLC-method for routine TDM of the novel antidepressant venlafaxine and its main relevant metabolites in serum
10. Therapeutic drug monitoring of sertraline: Variability factors as displayed in a clinical setting
11. Serum concentrations of fluoxetine in the clinical treatment setting
12. Steady-state plasma levels of nortriptyline in twins: Influence of genetic factors and drug therapy
13. Clinical significance of the sparteine/debrisoquine oxidation polymorphism
14. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: A first step towards subpopulation-specific dosages
15. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
16. Gender effects in pharmacokinetics and pharmacodynamics
17. Gender differences in pharmacokinetics
18. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6
19. Drug-drug interactions involving antidepressants: Focus on venlafaxine
20. Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms
21. Pharmacokinetic drug interactions of new antidepressants: A review of the effects on the metabolism of other drugs
22. Effect of venlafaxine on the pharmacokinetics of terfenadine
23. Editorial
24. Drugs and smoking
25. Effect of active and passive cigarette smoking on CYPIA2-mediated phenacetin disposition in Chinese subjects
26. Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways
27. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans
28. Human cytochrome P4501A2
29. Pharmacokinetic interactions of antidepressants
30. Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide